The Pharmaceutical company Windlas Biotech IPO will be Open Date is 4 Aug 2021 and close on 6 Aug 2021. The company can offer a fresh equity issue of ₹165 Crores and an Offer to sell 5,142,067 equity shares through an Offer for Sale. And according to this DRHP, the company will also consider pre-IPO (Initial Public Offer) placements up to 50 Crores.
The funds raised from this Windlas Biotech IPO will be used by the company to reduce its debt and for general corporate expenses and to purchase the equipment required to expand the facility at Dehradun Plant-IV and the injectable feed capacity at the facility at Dehradun Plant-II. Will be done to add.
Let me tell you that Windlas Biotech Ltd company is in the domestic pharmaceutical formulation contract development and manufacturing business. And it is one of the top five players in pharmaceutical formulation contracts, development, and manufacturing in India. The company formulations sell their branded products to many in the CDMO industry, in addition to providing services and products in the CDMO market, in the business generics and OTC markets, as well as in export general products.
Windlas Biotech IPO Review :
■ Coming Soon
Windlas Biotech IPO Date & Price Band & Details :
|IPO Open :||4 Aug 2021|
|IPO Close :||6 Aug 2021|
|IPO Size :||₹401.53. Cr|
|Face Value :||₹5 Rs. Equity Share|
|Price Band :||₹448–₹460 Per Share|
|Listing On :||BSE, NSE|
|Issue Size :||₹401.53. Cr|
|Fresh Issue :||₹165 Cr|
|Offer For Sale :||₹236.53. Cr|
Windlas Biotech IPO Market Lot :
Windlas Biotech IPO Minimum Market lot is 1 Lot with 30 shares with ₹13,800 Application amount. The retail investors can apply up to 14 lots with 420 Shares or ₹193,200 amounts.
|Minimum Lot Size :||1 Lot|
|Minimum Share :||13|
|Minimum Amount :||₹13,800|
|Maximum Lot Size :||14 Lot|
|Maximum shares :||420|
|Maximum Amount :||₹193,200|
Windlas Biotech IPO Shares Offer :
A total of 87,29,023 shares are to be bid for the public issue by Windlas Biotech IPO with 35,86,956 for Fresh issue and 51,42,067 for an offer for sale Shares.
|Fresh issue :||35,86,956||₹165 Cr|
|Offer For Sale :||51,42,067||₹236.53 Cr|
Windlas Biotech IPO Reservation :
Windlas Biotech IPO Total Reservation of – shares are to be bid for the public issue by Windlas Biotech IPO with 43,64,511 for QIB and 13,09,352 for NII 30,55,170 For RII & – Shares EMP.
|QIB :||50 %||43,64,511||₹200.76 Cr|
|NII :||15 %||13,09,352||₹60.23 Cr|
|RII :||35 %||30,55,170||₹140.53 Cr|
|EMP :||– %||–||₹|
|Total :||100 %||87,29,023||₹401.53 Cr|
Windlas Biotech IPO Dates :
Windlas Biotech IPO Date is 4 Aug 2021 and closes on 6 Aug 2021. The allotment will be finalized on 11 Aug 2021 and the IPO may list on 17 Aug 2021.
|Open Date :||4 Aug 2021|
|Close Date :||6 Aug 2021|
|Allotment Date :||11 Aug 2021|
|Refund Date :||12 Aug 2021|
|Share Credit Date :||13 Aug 2021|
|Listing Date :||17 Aug 2021|
Windlas Biotech IPO Form :
There are two ways to apply in Windlas Biotech IPO. You can apply for Windlas Biotech IPO through ASBA available in your bank account. You have to go to your online bank login and select Windlas Biotech IPO in the Invest section and apply through your bank account. Another option is you can apply Windlas Biotech IPO through IPO form download through NSE and BSE. See the Windlas Biotech IPO Form – Download the NSE Form and BSE Form IPO Form, fill it, and submit it to your bank or your broker.
Windlas Biotech Company Financial Report (Cr) :
About Windlas Biotech Company
Our Company was incorporated as ‘Windlas Biotech Limited’ on February 19, 2001, at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by the Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana, at New Delhi (“RoC Delhi”). Our Company received the certificate for commencement of business on March 5, 2001, from the RoC Delhi. The registered office of our Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by our Shareholders on August 22, 2009.
The alteration with respect to the place of the registered office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010, and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand at Kanpur on February 18, 2011. Subsequently, our Company was converted into a private limited company pursuant to a special resolution passed by our Shareholders on March 30, 2016, and a fresh certificate of incorporation consequent upon conversion and change of name to ‘Windlas Biotech Private Limited’ was granted by the Registrar of Companies, Uttarakhand at Kanpur on July 22, 2016.
|Read also: All Upcoming IPO Grey Market Premium 2021|
Our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders on April 3, 2021, and the name of our Company was changed to ‘Windlas Biotech Limited’. A fresh certificate of incorporation dated April 15, 2021, consequent upon change of name on conversion to a public limited company was granted by the Registrar of Companies, Uttarakhand at Dehradun.
We are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low solubility.
we provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost. In Fiscal 2020, our market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: CRISIL Report). In addition to providing services and products in the CDMO market, we also sell our own branded products in the trade generics and OTC markets as well as export generic products to several countries.
|Read also:- Share Buyback List 2021|
CDMO Services and Products. Our CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end-users. In Fiscal 2020 and the nine months ended December 31, 2020, our CDMO Services and Products SBV accounted for 87.36% and 85.73%, respectively, of our total revenue from operations. Revenues from CDMO Services and Products SBV increased by 23.12% from ₹ 2,233.68 million in the nine months ended December 31, 2019, to ₹ 2,750.07 million in the nine months ended December 31, 2020.
Exports. Our Exports SBV is engaged in identifying high growth markets and opportunities in semi-regulated international markets as well as selected regulated markets, for developing and registering product applications to obtain marketing authorizations for generic medicines and health supplements and subsequently, sell such products to pharmaceuticals companies and pharmacies in the respective markets. In Fiscal 2020 and the nine months ended December 31, 2020, our Exports SBV accounted for 3.25% and 3.34%, respectively, of our total revenue from operations. Revenues from Export SBV increased by 26.83% from ₹ 84.57 million in the nine months ended December 31, 2019, to ₹ 107.26 million in the nine months ended December 31, 2020.
Our Company Strengths
- Leading CDMO in India with a focus on the chronic therapeutic category.
- Innovative portfolio of complex generic products supported by robust R&D capabilities.
- Efficient and quality compliant manufacturing facilities with significant entry barriers.
- Strong and long-term relationships with leading Indian pharmaceutical companies.
- Consistent track record of financial performance.
- Experienced Promoters and senior management with a professional and technically qualified team.
Company Promoters :
■ Vivek Dhariwal
Windlas Biotech Board of Directors
|Vivek Dhariwal||Chairman and Non-Executive Independent Director|
|Ashok Kumar Windlass||Wholetime Director|
|Hitesh Windlass||Managing Director|
|Manoj Kumar Windlass||Joint Managing Director|
|Pawan Kumar Sharma||Executive Director|
|Prachi Jain Windlass||Non-Executive Director|
|Srinivasan Venkataraman||Non-Executive Independent Director|
|Gaurav Gulati||Non-Executive Independent Director|
Quick Link :
Windlas Biotech IPO Lead Managers :
■ SBI Capital Markets Limited
■ DAM Capital Advisors Limited
■ IIFL Securities Limited
Windlas Biotech IPO Registrar :
Link Intime India Private Limited
C-101, 1st Floor
Lal Bhadur Shastri Marg
Mumbai 400 083
Tel: +91 22 4918 6200
E-mail: [email protected]
Note: Check Windlas Biotech IPO allotment status Visit IPOBAZAR Allotment Page And Search Your Registrar IPO Allotment Link. Click Here
Company Address :
Windlas Biotech Limited
40/1, Mohabewala Industrial Area
Dehradun 248 110
Windlas Biotech Limited
705-706, Vatika Professional Point
Sector-66, Golf Course Extension Road
Gurgaon 122 001
Windlas Biotech IPO FAQs :
What is Windlas Biotech IPO?
Windlas Biotech IPO is Mainboard IPO. They are going to raise ₹401.53. Crores via IPO. The issue is priced at ₹448-₹460 per equity share. The IPO is to be listed on NSE, BSE.
When Windlas Biotech IPO will open?
The IPO is to open on 4 Aug – 6 Aug 2021 for QIB, NII & RII.
What is Windlas Biotech IPO Size?
Windlas Biotech IPO size is ₹401.53 Crores.
What is the Fresh issue size of Windlas Biotech IPO?
The Fresh issue size of Windlas Biotech IPO ₹165 Cr.
What is the Offer For Sale size of Windlas Biotech IPO?
The Offer For Sale size of Windlas Biotech IPO ₹236.53 Cr.
What is Windlas Biotech IPO Price Band?
Windlas Biotech IPO Price Band is ₹448-₹460 Per share.
What is Windlas Biotech IPO Minimum and Maximum Lot Size?
The minimum bid is 1 Lot 13 Shares with ₹13,800 amount while the maximum bid is 14 Lot 420 shares with ₹193,200.
What is Windlas Biotech IPO Investors Portion?
The investors’ portion for QIB 50%, NII 15%, RII 35%.
What is Windlas Biotech IPO Allotment Date?
Windlas Biotech IPO allotment date is 11 Aug 2021.
What is Windlas Biotech IPO Listing Date?
Windlas Biotech IPO listing date is 17 Aug 2021. The IPO to list on NSE, BSE.
How to Apply the Windlas Biotech IPO through Zerodha?
Log in to Console in Zerodha Website. Go to Portfolio and Click on IPO. You will see the IPO Name “Windlas Biotech IPO”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate.
How to Apply the Windlas Biotech IPO through Upstox?
Log in to Upstox Website or app. Go to Portfolio and Click on IPO. You will see the IPO Name “Windlas Biotech IPO”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate.
How to Apply the Windlas Biotech IPO through Groww?
Log in to Groww Website or app. Now you can see IPOs and Click on IPO. You will see the IPO Name “Windlas Biotech IPO”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate.
How to Apply the Windlas Biotech IPO through Paytm Money?
Log in to the Paytm Money Website or app. Now you can see Invest is IPOs Section and Click on IPO. You will see the IPO Name “Windlas Biotech IPO”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate.
|Windlas Biotech IPO GMP: Click Here|
Windlas Biotech IPO Subscription: Click Here
Windlas Biotech IPO Allotment: Click Here
Windlas Biotech IPO Listing: Click Here
All Windlas Biotech IPO-related links are available here. If you want to know the details then click on Click Here Link.
Disclaimer: STOCK MARKET INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.